Table 1.
Clinical and demographic characteristics of patients with active ulcerative colitis (n = 149)
| CMV (+) n = 34 | CMV (-) n = 115 | P value | |
| Sex (male/female) | 19/15 | 64/51 | 0.981 |
| Age at UC diagnosis (yr) | 42.3 ± 14.4 | 29.0 ± 14.4 | < 0.001 |
| Age at admission (yr) | 46.9 ± 18.1 | 35.0 ± 15.6 | < 0.001 |
| Disease duration (yr) | 4.6 ± 4.9 | 6.0 ± 7.4 | 0.294 |
| Clinical course | |||
| Relapse | 23 (67.6%) | 79 (68.7%) | 0.908 |
| Chronic active | 4 (11.8%) | 11 (9.6%) | 0.708 |
| First attack | 7 (20.6%) | 25 (21.7%) | 0.886 |
| Disease extent | |||
| Extensive UC (pancolitis) | 28 (82%) | 52 (45%) | < 0.001 |
| Left-sided UC/proctitis | 6 (18%) | 63 (55%) | - |
| BMI at admission | 19.5 ± 3.2 | 18.9 ± 3.1 | 0.384 |
| Severity | |||
| Severe | 11 (32%) | 27 (23%) | 0.297 |
| Moderate | 23 (68%) | 88 (77%) | - |
| Laboratory data at admission | |||
| CRP (mg/dL) | 3.4 ± 4.1 | 3.8 ± 5.4 | 0.685 |
| WBC (× 103/μL) | 8.7 ± 3.7 | 9.9 ± 4.2 | 0.132 |
| Hemoglobin (g/dL) | 11.4 ± 1.8 | 11.7 ± 1.2 | 0.387 |
| Platelet (× 103/μL) | 321.0 ± 118.9 | 349.9 ± 120.2 | 0.219 |
| Total cholesterol (mg/dL) | 155.3 ± 39.7 | 155.1 ± 44.3 | 0.979 |
| Albumin (g/dL) | 3.0 ± 0.54 | 3.4 ± 0.68 | 0.002 |
| Medication | |||
| Total lifetime systemic steroid dose before admission (g) | 4.69 ± 5.80 | 4.86 ± 8.45 | 0.892 |
| Total systemic steroid dose for 4 wk before admission (mg) | 1083.4 ± 1113.5 | 245.5 ± 328.4 | < 0.001 |
| Total systemic steroid dose for 1 wk before admission (mg) | 260.7 ± 103.9 | 92.3 ± 117.0 | < 0.001 |
| Systemic steroid dose on the day at admission (mg) | 37.5 ± 15.0 | 13.9 ± 17.6 | < 0.001 |
| 5-ASA | 29 (85.3%) | 82 (71.3%) | 0.100 |
| SASP | 1 (2.9%) | 10 (8.7%) | 0.260 |
| Cytapheresis | 5 (15%) | 11 (9.6%) | 0.395 |
| Immunomodulator use | 8 (24%) | 20 (17%) | 0.421 |
| AZA | 4 (12%) | 16 (14%) | 0.747 |
| 6-MP | 2 (5.9%) | 2 (1.7%) | 0.177 |
| Tacrolimus | 2 (5.9%) | 2 (1.7%) | 0.177 |
| Infliximab use | 5 (15%) | 7 (6.1%) | 0.105 |
| Family history of IBD | 1 (2.9%) | 1 (0.87%) | 0.356 |
| PSC | 0 | 2 (1.7%) | - |
| Outcome | |||
| Ganciclovir use | 26 (76%) | 0 | - |
| Colectomy | 17 (50%) | 37 (32%) | 0.058 |
| Colectomy for cancer or dysplasia | 0 | 4 (3.5%) | - |
Values presented as mean ± SD or number (%) as appropriate. CMV: Cytomegalovirus; CRP: C-reactive protein; WBC: White blood count; BMI: Body mass index; 5-ASA: 5-aminosalicylate acid; SASP: Salicylazosulfapyridine; AZA: Azathioprine; 6-MP: 6-mercaptopurine; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; PSC: Primary sclerosing cholangitis.